Hemoglobin as a peroxidase and drug target for oxidative stress-related diseases
Won, W.; Lee, E. H.; Gotina, L.; Chun, H.; Park, U.; Lee, J.-H.; Kim, D.; Kim, T. Y.; Choi, J.; Kim, Y.; Park, S. J.; Bhalla, M.; Lim, J.; Park, J.-H.; Oh, S.-J.; Ryu, H.; Pae, A. N.; Park, K. D.; Lee, C. J.
Show abstract
Summary paragraphHemoglobin (Hb) is well-known for transporting oxygen in red blood cells within blood vessels1. Although Hb is also present in the brain2, its role remains poorly understood. Here, we show that Hb, found in astrocytes of neurodegenerative animal models and patients, displays significant antioxidant effects through its H2O2-decomposing peroxidase activity, and a small molecule enhancer boosts this activity, reducing aberrant H2O2 and mitigating H2O2-induced neurodegeneration. To counteract the harmful effects of aberrant H2O2-production in Alzheimers disease (AD), we developed KDS12025, a blood-brain barrier (BBB)-permeable small molecule that effectively enhances the peroxidase activity of Hb by a hundredfold, especially at a low level of Hb. KDS12025 and its analogs achieve this enhancement through its electron-donating amine group. KDS12025 reduces H2O2 levels in astrocytes, exhibits neuroprotective effects, and reverses memory impairment in AD models. Gene-silencing of Hb{beta} abrogates KDS12025s impact in both culture and animal models of AD. Moreover, KDS12025 prevented the death of dopaminergic neurons in a Parkinsons disease (PD) model without altering the oxygen-transporting function of Hb. KDS12025 extended survival and improved motor function even in the severe amyotrophic lateral sclerosis (ALS) mouse model. Our findings propose Hb as a new therapeutic target for neurodegenerative diseases, with KDS12025 emerging as a first-in-class drug candidate that enhances Hbs peroxidase activity to reduce H2O2. Boosting Hbs peroxidase activity with KDS12025 mitigates oxidative stress and alleviates neurodegeneration in AD, PD, and ALS with broad applicability for numerous oxidative-stress-driven diseases.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- PTP1B inhibition promotes microglial phagocytosis in Alzheimer's disease models by enhancing SYK signaling 94%
- S-Nitrosylation of CRTC1 in Alzheimer's disease impairs CREB-dependent gene expression induced by neuronal activity 94%
- ACSS2 upregulation enhances neuronal resilience to aging and tau-associated neurodegeneration 94%
Similar papers in this journal
- Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma 95%
- Emergence of stealth polymorphs that escape α-synuclein amyloid monitoring, take over and acutely spread in neurons 94%
- Small molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's disease 93%
Similar papers in this journal
- Phosphorylation and O-GlcNAcylation at the same alpha-synuclein site generate distinct fibril structures 94%
- Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer’s disease proteopathology for precision medication 94%
- Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.